Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
99 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Neisseria meningitidis Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Neisseria meningitidis Infections - Pipeline Review, H1 2016', provides an overview of the Neisseria meningitidis Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections - The report reviews pipeline therapeutics for Neisseria meningitidis Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Neisseria meningitidis Infections therapeutics and enlists all their major and minor projects - The report assesses Neisseria meningitidis Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Neisseria meningitidis Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Neisseria meningitidis Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Neisseria meningitidis Infections Overview 10 Therapeutics Development 11 Pipeline Products for Neisseria meningitidis Infections - Overview 11 Pipeline Products for Neisseria meningitidis Infections - Comparative Analysis 12 Neisseria meningitidis Infections - Therapeutics under Development by Companies 13 Neisseria meningitidis Infections - Therapeutics under Investigation by Universities/Institutes 14 Neisseria meningitidis Infections - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Neisseria meningitidis Infections - Products under Development by Companies 18 Neisseria meningitidis Infections - Products under Investigation by Universities/Institutes 19 Neisseria meningitidis Infections - Companies Involved in Therapeutics Development 20 Beijing Minhai Biotechnology Co., Ltd 20 Beijing Tiantan Biological Products Co., Ltd. 21 Biological E. Limited 22 GlaxoSmithKline Plc 23 ImmunoBiology Limited 24 JN-International Medical Corporation 25 MGB Biopharma Limited 26 Panacea Biotec Limited 27 Pfizer Inc. 28 Sanofi Pasteur SA 29 Serum Institute of India Limited 30 Wellstat Vaccines, LLC 31 Neisseria meningitidis Infections - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Combination Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 (meningococcal [serotype X] + tetanus) (monovalent) vaccine - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 MenBioVax - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 meningococcal [serotype B] vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 meningococcal [serotype B] vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 meningococcal [serotype B] vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 meningococcal [serotype B] vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 meningococcal [serotype B] vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 meningococcal [serotype B] vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 meningococcal [serotypes A, C, W135] vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 meningococcal [serotypes A, C] vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 meningococcal [serotypes C, Y] vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 meningococcal [strain C2135] vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 meningococcal vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 meningococcal vaccine 2 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 MGBBP-3 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Neisseria meningitidis [serotype B] vaccine - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Neisseria meningitidis [serotype B] vaccine - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Nimenrix - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 TP-10 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Neisseria meningitidis Infections - Recent Pipeline Updates 78 Neisseria meningitidis Infections - Dormant Projects 86 Neisseria meningitidis Infections - Discontinued Products 89 Neisseria meningitidis Infections - Product Development Milestones 90 Featured News & Press Releases 90 Oct 09, 2015: Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents 90 Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine) 91 Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age 92 Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines 93 May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil 93 Mar 29, 2015: GSK statement on meningitis vaccination in the UK 94 Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk 94 Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents 95 Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease 96 Nov 18, 2014: TRUMENBA (Meningococcal Group B Vaccine) is Now Available 97 Appendix 98 Methodology 98 Coverage 98 Secondary Research 98 Primary Research 98 Expert Panel Validation 98 Contact Us 98 Disclaimer 99
List of Tables
Number of Products under Development for Neisseria meningitidis Infections, H1 2016 11 Number of Products under Development for Neisseria meningitidis Infections - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Neisseria meningitidis Infections - Pipeline by Beijing Its Minhai Biotechnology Co., Ltd, H1 2016 20 Neisseria meningitidis Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016 21 Neisseria meningitidis Infections - Pipeline by Biological E. Limited, H1 2016 22 Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 23 Neisseria meningitidis Infections - Pipeline by ImmunoBiology Limited, H1 2016 24 Neisseria meningitidis Infections - Pipeline by JN-International Medical Corporation, H1 2016 25 Neisseria meningitidis Infections - Pipeline by MGB Biopharma Limited, H1 2016 26 Neisseria meningitidis Infections - Pipeline by Panacea Biotec Limited, H1 2016 27 Neisseria meningitidis Infections - Pipeline by Pfizer Inc., H1 2016 28 Neisseria meningitidis Infections - Pipeline by Sanofi Pasteur SA, H1 2016 29 Neisseria meningitidis Infections - Pipeline by Serum Institute of India Limited, H1 2016 30 Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines, LLC, H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Assessment by Combination Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 36 Number of Products by Stage and Route of Administration, H1 2016 38 Number of Products by Stage and Molecule Type, H1 2016 40 Neisseria meningitidis Infections Therapeutics - Recent Pipeline Updates, H1 2016 78 Neisseria meningitidis Infections - Dormant Projects, H1 2016 86 Neisseria meningitidis Infections - Dormant Projects (Contd..1), H1 2016 87 Neisseria meningitidis Infections - Dormant Projects (Contd..2), H1 2016 88 Neisseria meningitidis Infections - Discontinued Products, H1 2016 89
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
